Sankarasubramanian Vishwanath, Chiravuri Srinivas, Mirzakhalili Ehsan, Anaya Carlos J, Scott John Ryan, Brummett Chad M, Clauw Daniel J, Patil Parag G, Harte Steven E, Lempka Scott F
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Neuromodulation. 2021 Jun;24(4):672-684. doi: 10.1111/ner.13329. Epub 2021 Jan 20.
BACKGROUND/OBJECTIVES: The physiological mechanisms underlying the pain-modulatory effects of clinical neurostimulation therapies, such as spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRGS), are only partially understood. In this pilot prospective study, we used patient-reported outcomes (PROs) and quantitative sensory testing (QST) to investigate the physiological effects and possible mechanisms of action of SCS and DRGS therapies.
We tested 16 chronic pain patients selected for SCS and DRGS therapy, before and after treatment. PROs included pain intensity, pain-related symptoms (e.g., pain interference, pain coping, sleep interference) and disability, and general health status. QST included assessments of vibration detection theshold (VDT), pressure pain threshold (PPT) and tolerance (PPToL), temporal summation (TS), and conditioned pain modulation (CPM), at the most painful site.
Following treatment, all participants reported significant improvements in PROs (e.g., reduced pain intensity [p < 0.001], pain-related functional impairment [or pain interference] and disability [p = 0.001 for both]; better pain coping [p = 0.03], sleep [p = 0.002]), and overall health [p = 0.005]). QST showed a significant treatment-induced increase in PPT (p = 0.002) and PPToL (p = 0.011), and a significant reduction in TS (p = 0.033) at the most painful site, but showed no effects on VDT and CPM. We detected possible associations between a few QST measures and a few PROs. Notably, higher TS was associated with increased pain interference scores at pre-treatment (r = 0.772, p = 0.009), and a reduction in TS was associated with the reduction in pain interference (r = 0.669, p = 0.034) and pain disability (r = 0.690, p = 0.027) scores with treatment.
Our preliminary findings suggest significant clinical and therapeutic benefits associated with SCS and DRGS therapies, and the possible ability of these therapies to modulate pain processing within the central nervous system. Replication of our pilot findings in future, larger studies is necessary to characterize the physiological mechanisms of SCS and DRGS therapies.
背景/目的:临床神经刺激疗法,如脊髓刺激(SCS)和背根神经节刺激(DRGS),其疼痛调节作用的生理机制仅得到部分理解。在这项前瞻性试点研究中,我们使用患者报告结局(PROs)和定量感觉测试(QST)来研究SCS和DRGS疗法的生理效应及可能的作用机制。
我们对16名入选接受SCS和DRGS治疗的慢性疼痛患者在治疗前后进行了测试。PROs包括疼痛强度、疼痛相关症状(如疼痛干扰、疼痛应对、睡眠干扰)和残疾情况,以及总体健康状况。QST包括在最疼痛部位对振动觉阈值(VDT)、压痛阈值(PPT)和耐受度(PPToL)、时间总和(TS)以及条件性疼痛调制(CPM)的评估。
治疗后,所有参与者报告PROs有显著改善(如疼痛强度降低[p < 0.001]、疼痛相关功能障碍[或疼痛干扰]和残疾情况改善[两者均为p = 0.001];疼痛应对能力提高[p = 0.03]、睡眠改善[p = 0.002])以及总体健康状况改善[p = 0.005])。QST显示,在最疼痛部位,治疗导致PPT(p = 0.002)和PPToL显著增加(p = 0.011),TS显著降低(p = 0.033),但对VDT和CPM无影响。我们检测到一些QST指标与一些PROs之间可能存在关联。值得注意的是,较高的TS与治疗前疼痛干扰评分增加相关(r = 0.772,p = 0.009);TS降低与治疗后疼痛干扰(r = 0.669,p = 0.034)和疼痛残疾(r = 0.690,p = 0.027)评分降低相关。
我们的初步研究结果表明,SCS和DRGS疗法具有显著的临床和治疗益处,以及这些疗法可能具有调节中枢神经系统内疼痛处理的能力。未来有必要在更大规模的研究中重复我们的试点研究结果,以明确SCS和DRGS疗法的生理机制。